BR0015699A - Formulação de solução aquosa de alfa-interferon - Google Patents
Formulação de solução aquosa de alfa-interferonInfo
- Publication number
- BR0015699A BR0015699A BR0015699-0A BR0015699A BR0015699A BR 0015699 A BR0015699 A BR 0015699A BR 0015699 A BR0015699 A BR 0015699A BR 0015699 A BR0015699 A BR 0015699A
- Authority
- BR
- Brazil
- Prior art keywords
- interferon
- aqueous solution
- formulation
- present
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
"FORMULAçãO DE SOLUçãO AQUOSA DE ALFA-INTERFERON". A presente invenção refere-se a uma formulação de solução aquosa que pode reter a atividade biológica e propriedades fisicoquímicas de <244>-interferon durante um longo período. Mais particularmente, a presente invenção refere-se a uma formulação de solução aquosa de <244>-interferon compreendendo <244>-interferon; um estabilizador; um agente de regulação de pressão osmótica; conservantes antimicrobianos selecionados do grupo consistindo em fenol, m-cresol ou mistura destes; e um sistema tampão. A formulação de solução aquosa da presente invenção tem muitas vantagens porque ela retém a atividade de <244>-interferon durante um longo período, elimina a nocividade potencial para o corpo humano minimizando a quantidade dos conservantes, e é muito estável.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-1999-0051481A KR100399156B1 (ko) | 1999-11-19 | 1999-11-19 | α-인터페론의 용액제형 |
PCT/KR2000/001322 WO2001035987A1 (en) | 1999-11-19 | 2000-11-17 | An aqueous solution formulation of alpha-interferon |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0015699A true BR0015699A (pt) | 2002-07-23 |
Family
ID=36782398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0015699-0A BR0015699A (pt) | 1999-11-19 | 2000-11-17 | Formulação de solução aquosa de alfa-interferon |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1231933B1 (pt) |
JP (1) | JP3893286B2 (pt) |
KR (1) | KR100399156B1 (pt) |
CN (1) | CN1203892C (pt) |
AR (1) | AR026507A1 (pt) |
AT (1) | ATE333891T1 (pt) |
AU (1) | AU777994B2 (pt) |
BR (1) | BR0015699A (pt) |
CA (1) | CA2391889A1 (pt) |
CY (1) | CY1105449T1 (pt) |
DE (1) | DE60029614T2 (pt) |
DK (1) | DK1231933T3 (pt) |
ES (1) | ES2267584T3 (pt) |
HU (1) | HUP0203706A3 (pt) |
MX (1) | MXPA02005105A (pt) |
PE (1) | PE20010903A1 (pt) |
PL (1) | PL356406A1 (pt) |
PT (1) | PT1231933E (pt) |
RU (1) | RU2232595C2 (pt) |
TR (1) | TR200201310T2 (pt) |
TW (1) | TWI223596B (pt) |
WO (1) | WO2001035987A1 (pt) |
ZA (1) | ZA200204096B (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8551469B2 (en) | 2001-02-28 | 2013-10-08 | Superlab Far East Limited | Treatment of tumors and viral diseases with recombinant interferon alpha |
CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
US6830744B2 (en) * | 2002-05-31 | 2004-12-14 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
US7585647B2 (en) | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
RU2447897C2 (ru) * | 2009-03-26 | 2012-04-20 | Сергей Юрьевич Родионов | Цитокинсодержащая композиция для лечения вирусных заболеваний |
KR20120130757A (ko) | 2010-02-26 | 2012-12-03 | 노보 노르디스크 에이/에스 | 안정한 항체 함유 조성물 |
CA2800188A1 (en) * | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
US20150283252A1 (en) | 2012-10-26 | 2015-10-08 | Lupin Limited | Stable pharmaceutical composition of peginterferon alpha-2b |
CN104888196B (zh) * | 2015-06-25 | 2018-07-06 | 北京三元基因药业股份有限公司 | 一种稳定的干扰素α多剂量笔注射液 |
CN105456186A (zh) * | 2015-12-24 | 2016-04-06 | 杭州嘉伟生物制品有限公司 | 一种生理平衡液的制备方法 |
CN114259556B (zh) * | 2021-12-24 | 2024-05-31 | 科兴生物制药股份有限公司 | 人干扰素α2b喷雾剂及其制备方法 |
CN114053397B (zh) * | 2022-01-17 | 2022-12-20 | 北京三元基因药业股份有限公司 | 一种稳定的干扰素多剂量注射液及其制备方法 |
CN115068592A (zh) * | 2022-06-27 | 2022-09-20 | 长春生物制品研究所有限责任公司 | 开封后常温稳定的重组人干扰素α1b滴眼液及制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766582A (en) * | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
JP2758154B2 (ja) * | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
-
1999
- 1999-11-19 KR KR10-1999-0051481A patent/KR100399156B1/ko not_active IP Right Cessation
-
2000
- 2000-11-16 AR ARP000106058A patent/AR026507A1/es unknown
- 2000-11-17 DK DK00976435T patent/DK1231933T3/da active
- 2000-11-17 WO PCT/KR2000/001322 patent/WO2001035987A1/en active IP Right Grant
- 2000-11-17 TW TW089124326A patent/TWI223596B/zh not_active IP Right Cessation
- 2000-11-17 PE PE2000001230A patent/PE20010903A1/es not_active Application Discontinuation
- 2000-11-17 BR BR0015699-0A patent/BR0015699A/pt not_active IP Right Cessation
- 2000-11-17 TR TR2002/01310T patent/TR200201310T2/xx unknown
- 2000-11-17 AU AU14216/01A patent/AU777994B2/en not_active Ceased
- 2000-11-17 DE DE60029614T patent/DE60029614T2/de not_active Expired - Fee Related
- 2000-11-17 HU HU0203706A patent/HUP0203706A3/hu unknown
- 2000-11-17 JP JP2001537977A patent/JP3893286B2/ja not_active Expired - Fee Related
- 2000-11-17 AT AT00976435T patent/ATE333891T1/de not_active IP Right Cessation
- 2000-11-17 CA CA002391889A patent/CA2391889A1/en not_active Abandoned
- 2000-11-17 MX MXPA02005105A patent/MXPA02005105A/es unknown
- 2000-11-17 CN CNB00815919XA patent/CN1203892C/zh not_active Expired - Fee Related
- 2000-11-17 PT PT00976435T patent/PT1231933E/pt unknown
- 2000-11-17 PL PL00356406A patent/PL356406A1/xx not_active IP Right Cessation
- 2000-11-17 ES ES00976435T patent/ES2267584T3/es not_active Expired - Lifetime
- 2000-11-17 RU RU2002116364/15A patent/RU2232595C2/ru not_active IP Right Cessation
- 2000-11-17 EP EP00976435A patent/EP1231933B1/en not_active Expired - Lifetime
-
2002
- 2002-05-23 ZA ZA200204096A patent/ZA200204096B/xx unknown
-
2006
- 2006-08-30 CY CY20061101228T patent/CY1105449T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2267584T3 (es) | 2007-03-16 |
DE60029614T2 (de) | 2007-07-12 |
MXPA02005105A (es) | 2002-11-07 |
JP3893286B2 (ja) | 2007-03-14 |
DK1231933T3 (da) | 2006-10-30 |
CN1203892C (zh) | 2005-06-01 |
EP1231933A1 (en) | 2002-08-21 |
DE60029614D1 (de) | 2006-09-07 |
ATE333891T1 (de) | 2006-08-15 |
RU2232595C2 (ru) | 2004-07-20 |
HUP0203706A2 (hu) | 2003-03-28 |
ZA200204096B (en) | 2003-02-26 |
WO2001035987A1 (en) | 2001-05-25 |
PL356406A1 (en) | 2004-06-28 |
JP2003514027A (ja) | 2003-04-15 |
HUP0203706A3 (en) | 2004-12-28 |
PT1231933E (pt) | 2006-10-31 |
TWI223596B (en) | 2004-11-11 |
EP1231933B1 (en) | 2006-07-26 |
AR026507A1 (es) | 2003-02-12 |
CY1105449T1 (el) | 2010-04-28 |
RU2002116364A (ru) | 2004-01-20 |
KR20010047312A (ko) | 2001-06-15 |
CN1391478A (zh) | 2003-01-15 |
AU777994B2 (en) | 2004-11-11 |
AU1421601A (en) | 2001-05-30 |
CA2391889A1 (en) | 2001-05-25 |
PE20010903A1 (es) | 2001-08-31 |
KR100399156B1 (ko) | 2003-09-26 |
TR200201310T2 (tr) | 2002-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0015699A (pt) | Formulação de solução aquosa de alfa-interferon | |
DZ2906A1 (fr) | Livraison d'agent actif atomisé par modulation résistance de débit. | |
BR0013010A (pt) | Formulação de cloreto de sódio de moxifloxacina | |
CY1107992T1 (el) | Συνθεσεις πολυαμιδο-αμικου οξεος υδατικης βασεως | |
DE69926386D1 (de) | Propofol-formulierung | |
BRPI9906372B8 (pt) | composição farmaceutica aquosa para aplicação na mucosa | |
BR0313060A (pt) | Composições farmacêuticas aquosas de 2,6-diisopropilfenol | |
BR0014209A (pt) | Sistema para o tratamento de tecido lesionado, e, composição de tratamento para aplicação em e penetração para dentro de tecido lesionado | |
MXPA04003211A (es) | Formulaciones de gel hidroalcoholicas y desinfectantes para la piel de accion suave. | |
DZ2892A1 (fr) | Livraison d'agent actif atomisé par modulation résistance de débit. | |
ATE210943T1 (de) | Ophthalmologisches abgabesystem | |
BR0210630A (pt) | Sistema fornecedor de liberação prolongada | |
BR9912508A (pt) | Métodos e composições transdérmicas para alìvio da dor | |
BR0109934A (pt) | Preparação e prevenção de diarréia de ácido biliar | |
BR0007632A (pt) | Composições sinérgicas antimicrobianas para lavagem da pele | |
BR0013009A (pt) | Uso de antagonistas de cgrp e de inibidores de liberação de cgrp para combate a jatos quentes menopáusicos | |
DE60026618D1 (de) | Gamma-ifn flüssigtropfenaerosol und verfahren | |
BR9909262A (pt) | Composição para axilas | |
HRP20020298B1 (en) | Pharmaceutical solutions of levosimendan | |
BR9712409A (pt) | Formulação lìquida antimicrobiana aquosa para limpeza | |
BRPI0014878B8 (pt) | composição farmacêutica contendo ciclosonida para aplicação à mucosa | |
BR9909357A (pt) | Solução ou suspensão de mirtazapina em mistura com água, formulação farmacêutica compreendendo mirtazapina, e, uso de mirtazapina | |
BR0010983A (pt) | Preparações para a aplicação de agentes antiinflamatórios | |
DE69527713D1 (de) | Verbindunngen und zusammensetzungen zur verabreichung via inhalation und insufflierung | |
BR0102940A (pt) | Agente para o tratamento de doença de parkinson compreendendo um agente de melhora da função de astrócitos como ingrediente ativo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A,7 ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008. |